Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 37,400 shares, a growth of 80.7% from the November 30th total of 20,700 shares. Based on an average daily volume of 18,200 shares, the short-interest ratio is presently 2.1 days.
Monterey Bio Acquisition Stock Performance
MTRYW stock opened at $0.02 on Friday. Monterey Bio Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.41. The business's 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05.
Get Monterey Bio Acquisition alerts:Institutional Inflows and Outflows
An institutional investor recently bought a new position in Monterey Bio Acquisition stock. Ramius Advisors LLC purchased a new position in Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 286,110 shares of the company's stock, valued at approximately $27,000.
Monterey Bio Acquisition Company Profile
(Get Rating)Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp.
Featured Articles
- Get a free copy of the StockNews.com research report on Monterey Bio Acquisition (MTRYW)
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
Receive News & Ratings for Monterey Bio Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monterey Bio Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.